Connected evidence for precision oncology email
Dear Kenneth,
As targeted cancer therapies become more specialized, real-world evidence programs must keep pace with more complex data needs. For therapies dependent on novel biomarkers, traditional approaches may not always provide the scale, speed, or granularity required.
This IQVIA white paper outlines a comprehensive approach to RWE generation for targeted oncology therapies
Download the paper to explore
- Why biomarker adoption and testing variability can limit evidence generation
- How linked biomarker and clinical data can improve RWE study design
- How archival tissue testing can broaden understanding of under-tested biomarkers
- How AI-ready imaging and pathology data may support future precision oncology use cases
- How stronger RWE programs can support development, access, and adoption
Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.
By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).
© 2026 Marketing Masters Hub. All rights reserved.